Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections

por Ramdial, Jeremy L., Saliba, Rima M., Alousi, Amin M., Rondon, Gabriela, Chen, Julianne, Ledesma, Celina, Shpall, Elizabeth J., Chemaly, Roy, Champlin, Richard E.
Publicado 2021

Treatment of allosensitized patients receiving allogeneic transplantation

por Ciurea, Stefan O., Al Malki, Monzr M., Kongtim, Piyanuch, Zou, Jun, Aung, Fleur M., Rondon, Gabriela, Chen, Julianne, Taniguchi, Michiko, Otoukesh, Salman, Nademanee, Auayporn, Forman, Stephen J., Champlin, Richard, Gendzekhadze, Ketevan, Cao, Kai
Publicado 2021

Long-Term Follow-up Outcomes of Patients That Underwent Allogeneic or Autologous Hematopoietic Transplant Shortly after a COVID-19 Infection

por Marinos, Alejandro, Ramdial, Jeremy L, Saliba, Rima M., Khawaja, Fareed, Alousi, Amin M., Rondon, Gabriela, Chen, Julianne, Ledesma, Celina, Chemaly, Dr. Roy F., Champlin, Richard E., Marin, David, Daher, May, Rezvani, Katayoun, Shpall, Elizabeth J.
Publicado 2023

Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation

por Saliba, Rima M., Veltri, Lauren, Rondon, Gabriela, Chen, Julianne, Al-Atrash, Gheath, Alousi, Amin, Martinez, Charles, Augustine, LaJerald, Hosing, Chitra M., Oran, Betul, Rezvani, Katayoun, Shpall, Elizabeth J., Kebriaei, Partow, Khouri, Issa F., Popat, Uday, Champlin, Richard E., Ciurea, Stefan O.
Publicado 2020

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation

por Konopleva, Marina, Benton, Christopher B., Thall, Peter F., Zeng, Zhihong, Shpall, Elizabeth, Ciurea, Stefan, Kebriaei, Partow, Alousi, Amin, Popat, Uday, Anderlini, Paolo, Nieto, Yago, Parmar, Simrit, Qiao, Wei, Chen, Julianne, Rondon, Gabriela, McMullin, Becky, Wang, Rui-Yu, Lu, Hongbo, Schober, Wendy, Woodworth, Glenda, Gulbis, Alison, Cool, Rita, Andreeff, Michael, Champlin, Richard
Publicado 2015

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation

por Andersson, Borje S., Thall, Peter F., Ma, Junsheng, Valdez, Benigno C., Bassett, Roland, Chen, Julianne, Ahmed, Sairah, Alousi, Amin, Bashir, Qaiser, Ciurea, Stefan, Gulbis, Alison, Cool, Rita, Kawedia, Jitesh, Hosing, Chitra, Kebriaei, Partow, Kornblau, Steve, Myers, Alan, Oran, Betul, Rezvani, Katayoun, Shah, Nina, Shpall, Elizabeth, Parmar, Simrit, Popat, Uday R., Nieto, Yago, Champlin, Richard E.
Publicado 2022

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients

por Andersson, Borje S., Thall, Peter F., Valdez, Benigno C., Milton, Denái R., Al-Atrash, Gheath, Chen, Julianne, Gulbis, Alison, Chu, Diem, Martinez, Charles, Parmar, Simrit, Popat, Uday, Nieto, Yago, Kebriaei, Partow, Alousi, Amin, de Lima, Marcos, Rondon, Gabriela, Meng, Qing H., Myers, Alan, Kawedia, Jitesh, Worth, Laura L., Fernandez-Vina, Marcelo, Madden, Timothy, Shpall, Elizabeth J., Jones, Roy B., Champlin, Richard E.
Publicado 2016

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities

por Popat, Uday R., Pasvolsky, Oren, Bassett Jr., Roland, Mehta, Rohtesh S., Olson, Amanda, Chen, Julianne, Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Gulbis, Alison M., Hosing, Chitra M., Im, Jin S., Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Oran, Betul, Saini, Neeraj, Shigle, Terri Lynn, Srour, Samer A., Ramdial, Jeremy L., Rezvani, Katayoun, Qazilbash, Muzaffar H., Andersson, Borje S., Champlin, Richard E., Shpall, Elizabeth J.
Publicado 2023